Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Biden Calls For Lower Prices Of Ozempic, Similar Drugs

US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."

International Business Times

3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

Barchart

Chart of the Day: Eli Lilly - More New Highs

Author's Note: Last featured 10/26/23 at $586.37. Gained 54% since that date. The Chart of the Day belongs to the drug manufacturer Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk’s Wegovy may just have two years to take over China’s market for weight loss drugs

Novo Nordisk's China patent on Wegovy's active ingredient expires in 2026, much earlier than its patents in the U.S., Japan and Europe.

Fortune

Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy

The Guardian - UK

Lawsuit could challenge trust in Ozempic and other popular weight loss drugs

The manufacturers of the most popular weight loss drugs are being challenged in court.

The Conversation

3 Stocks Most Likely to Join the $1 Trillion Market Cap Club in the Next 5 Years

With a solid product portfolio, brand strength, and a thirst for innovation, these three companies are on the right track.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Alzheimer's drug that can slow disease gets backing from FDA advisers

Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia

The Independent UK

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

Barchart

Eli Lilly Stock: Is LLY Outperforming the Healthcare Sector?

Eli Lilly has outperformed the healthcare sector over the past three months, but analysts remain cautiously optimistic about the stock’s prospects.

Barchart

In China, weight-loss drugs are becoming big business

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

Al Jazeera

3 Pharma Stocks Poised for Big Returns This Summer

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs and the incorporation of cutting-edge technologies into drug manufacturing. Hence, pharma stocks Eli Lilly (LLY), Green Thumb Industries (GTBIF), and Supernus Pharmaceuticals (SUPN) might be worth buying for returns this summer. Read more….

StockNews.com

Do Wall Street Analysts Like Eli Lilly Stock?

Eli Lilly stock has outperformed the broader market over the past year, and Wall Street analysts remain optimistic about the stock’s prospect.

Barchart

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Reason

It's Time for Over-the-Counter Ozempic

There's an easy way to lower the cost of next-generation weight-loss drugs.

Barchart

1 'Strong Buy' Dividend Stock to Buy and Hold

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

StockNews.com

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Al Jazeera

What is behind the insulin shortage in the US?

Pharma companies are slashing insulin production in favour of more lucrative weight-loss drugs.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

Barchart

Stocks Sink on Concern the Fed Will Keep Interest Rates Higher for Longer

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -1.57%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.92%. US stock indexes Tuesday finished sharply lower. Signs of persistent wage pressure pushed bond...

Kiplinger

Stock Market Today: Stocks Sell Off Ahead of Fed Decision

Stocks sold off sharply Tuesday as anxiety set in ahead of Wednesday's policy statement from the Federal Reserve.

Barchart

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

Top News

Zepbound Shows Promise In Treating Sleep Apnea

Eli Lilly's Zepbound drug shows promise in treating obstructive sleep apnea by reducing symptoms and promoting weight loss.

The Guardian - UK

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

The Guardian - AU

Alzheimer’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays

The benefits of drugs such as donanemab, aducanumab and lecanemab are proving harder to quantify than potential harms, experts say

1 … 20 21 22 23

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

1,336 stories

Broadcom

1,071 stories

Warner Bros Discovery

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.